SCHEMBL620969

SCHEMBL620969

COC(=O)C=C1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL873013 0.95 TSHR (0.42)
SCHEMBL8098922 0.93 TSHR (0.41)
SCHEMBL106091 0.93 TSHR (0.41)
SCHEMBL8089816 0.93 TSHR (0.41)
SCHEMBL518574 0.90
SCHEMBL1035256 0.82 TSHR (0.43)
SCHEMBL1187818 0.82 TSHR (0.43)
SCHEMBL25223710 0.80 TSHR (0.46)
Hydrochloric Acid SCHEMBL23037273 0.80 TSHR (0.42)
SCHEMBL3264014 0.80 TSHR (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043625-B2 Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-23 US disclosed
US-12043625-B2 Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-23 US disclosed
US-12043625-B2 Pyridine derivatives with c-linked cyclic substituents as cGAS inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-07-23 US disclosed
US-20240158412-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF FAXIAN THERAPEUTICS, LLC 2024-05-16 US disclosed
EP-4337327-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2024-03-20 EP disclosed
EP-4288442-A1 UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF Faxian Therapeutics, LLC (US) 2023-12-13 EP disclosed
WO-2023109540-A1 HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2023-06-22 WO disclosed
US-20230002401-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-01-05 US disclosed
US-20230002401-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-01-05 US disclosed
WO-2022238335-A1 PYRIDINE DERIVATIVES WITH C-LINKED CYCLIC SUBSTITUENTS AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2022-11-17 WO disclosed
US-7842703-B2 Substituted benzofused derivatives and their use as vanilloid receptor ligands GLENMARK PHARMACEUTICALS S.A. (CH) 2010-11-30 US disclosed
US-20100249229-A1 BICYCLIC gamma-AMINO ACID DERIVATIVE DAIICHI SANKYO COMPANY, LTD. (JP) 2010-09-30 US disclosed
EP-2192109-A1 BICYCLIC -AMINO ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-06-02 EP disclosed
US-20090306197-A1 Substituted Chromanol Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2009-12-10 US disclosed
US-20090306197-A1 Substituted Chromanol Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2009-12-10 US disclosed
US-20090306197-A1 Substituted Chromanol Derivatives and Their Use BAYER HEALTHCARE AG (DE) 2009-12-10 US disclosed
US-20080269253-A1 Substituted Benzofused Derivatives and Their Use as Vanilloid Receptor Ligands GLENMARK PHARMACEUTICALS, S.A. (CH) 2008-10-30 US disclosed
EP-1931681-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS Glenmark Pharmaceuticals S.A. (CH) 2008-06-18 EP disclosed
WO-2007107243-A1 SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE BAYER HEALTHCARE AG (DE) 2007-09-27 WO disclosed
WO-2007042906-A1 SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS GLENMARK PHARMACEUTICALS S.A. (US) 2007-04-19 WO disclosed